Mammalian target of rapamycin (mTOR) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|113|3|376-382

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.113, Iss.3, 2014-03, pp. : 376-382

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mammalian target of rapamycin (mTOR)‐related non‐infectious pneumonitis: a potential biomarker of clinical benefit?

By  

BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. : 350-351

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

By  

Oncology, Vol. 85, Iss. 1, 2013-06 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

By  

HEPATOLOGY, Vol. 54, Iss. 4, 2011-10 ,pp. : 1199-1207

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phosphorylation of the ribosomal protein S6, a marker of mTOR (mammalian target of rapamycin) pathway activation, is strongly increased in hypertrophic scars and keloids

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 5, 2015-05 ,pp. : 1415-1417

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara   Cho Daniel C  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite